Unigen announces settlement in patent infringement case
Leiner admitted the validity of the Unigen patents and agreed not to sell any products containing the ingredients Scutellaria and Acacia catechu while the Unigen patents are in force, unless it were to receive a license to do so from Unigen.
Unigen Pharmaceuticals announced it has settled a case, brought in the U.S. District Court in Seattle, alleging Leiner Health Products, Safeway and Target had violated patents Unigen holds on products containing the ingredients Scutellaria and Acacia catechu. Unigen produces those ingredients on an exclusive basis in the food, drug, and mass market for one of its licensees.
Leiner, a company that manufactures private-label nutritional products for major retailers such as Safeway, Longs Drugs, and Albertson's, used Scutellaria and Acacia catechu to create an advanced glucosamine and chondroitin joint care product it then sold to major retail customers under trade names such as Bones and Joints and Advanced Triple Strength Formula. Leiner admitted the validity of the Unigen patents and agreed not to sell any products containing the ingredients Scutellaria and Acacia catechu while the Unigen patents are in force, unless it were to receive a license to do so from Unigen.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
